期刊文献+

高效液相色谱法研究甲氨蝶呤和特立氟胺在大鼠体内的药代动力学 被引量:1

Pharmacokinetic Research of Methotrexate and Teriflunomide in Rats by HPLC
下载PDF
导出
摘要 采用高效液相色谱法(HPLC)建立大鼠血浆中的甲氨蝶呤(MTX)和特立氟胺(TEF)的检测方法,研究大鼠体内MTX和TEF的药代动力学。色谱柱为Aglient ZORBAX SB-C18柱(4.6 mm×250 mm,5μm);流动相:50 m M乙酸钠溶液—乙腈(体积比85:15);检测波长为300 nm;柱温为30℃;流速为1.5 m L/min。大鼠采用静脉注射给药,药动学参数采用DAS 2.0计算。该HPLC方法可用于大鼠血浆中MTX和TEF的同时测定,方法准确,快速,灵敏度高,重复性好,适用于大鼠体内MTX和TEF药物代谢动力学的研究。 A HPLC method was established for determination of plasma concentration of methotrexate and teriflunomide and study on the pharmacokinetics of methotrexate and teriflunomide in rats. The chromatographic conditions were as follows: a Aglient ZORBAX SB-C18 chromatographic column(250 mm × 4.6 mm, 5 μm) was used at 30 ℃. The mobile phase consisted of 50 m M sodium acetate solution-acetonitrile(85:15, v/v) and was pumped at a flow rate of 1.5 m L?min-1. The determination wavelength was 300 nm. Rats were received a single dose of drugs by intravenous injection. The pharmacokinetic parameters of methotrexate and teriflunomide were calculated with DAS 2.0 software. The HPLC method for determining methotrexate and teriflunomide concentration in rat plasma is accurate, rapid, simple, sensitive and repeatability and can be applied to pharmacokinetic studies of methotrexate and teriflunomide.
作者 杨国韬 兰艳
出处 《当代化工》 CAS 2015年第12期2916-2918,共3页 Contemporary Chemical Industry
关键词 高效液相色谱法 甲氨蝶呤 特立氟胺 大鼠 药代动力学 HPLC Methotrexate Teriflunomide Rats Pharmacokinetics
  • 相关文献

参考文献6

二级参考文献51

  • 1彭磊,张茜,金涌,李俊.来氟米特活性代谢产物A771726在小鼠体内的药动学研究[J].安徽医药,2006,10(10):729-730. 被引量:5
  • 2Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis[J]. Nat Rev Drug Diseov, 2003, 2: 473-488.
  • 3Fox RI, Herrmann ML, Frangou CG, etal. Mechanism of ac- tion of leflunomide in rheumatoid arthritis[J]. Clin Immunol, 1999, 93(3): 198-208.
  • 4Sakellariou GT, Sayegh FE, Kapetanos GA, et al. Efficacy of leflunomide addition in relation to prognostic factors for pa tients with active early rheumatoid arthritis failing to metho-trexate in daily practice [J]. Ciin Rheumatol, 2012,31 (1) 163-167.
  • 5Kraan MC, Smeets TJM, van Loon MJ, et al. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis [J]. Ann Rheum Dis, 2004, 63: 1056- 1061.
  • 6Li WD, Ran GX, Teng HL, etal. Dynamic effcets of lefluno- mide on IL- 1, IL - 6 and TNF - alpha activity produced from periton calm acrophagesin adjuvant arthritis rats[J]. Acta Pharmacoi Sin, 2002, 23(8): 752 756.
  • 7Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Con- ference[J]. J Am Acad Dermatol, 2009, 60: 824-837.
  • 8Petra BG, Iztok G, BlaiR, et al. An investigation of the influ- ence o[ CYP1A2 and CYP2C19 Genetic polymorphism on 2- Cyano-3 hydroxy-N E 4-( trifluoromethyl ) phenyl 1-2 butenamide (A77 1726) pharmacokinetics in leflunomide-trea- ted patients with rheumatoid arthritis [J]. Drug Metabolism And Disposition, 2009 37:2061-2068.
  • 9Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?[J]. Curr Opin Rheumatol, 2011, 23(3): 288-292.
  • 10Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver en zyme tests among patients with rheumatoid arthritis or psoriat ic arthritis treated with rnethotrexate and/or leflunomide [J]. Ann Rheum Dis, 2010, 69(1): 43-47.

共引文献39

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部